AstraZeneca: Lynparza Combo Recommended in EU for Prostate Cancer
14 November 2022 - 6:44PM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Monday that a Lynparza combination has been
recommended for marketing authorization in the European Union for
the treatment of metastatic castration-resistant prostate
cancer.
The Anglo-Swedish pharma major said Lynparza in combination with
abiraterone and prednisone or prednisolone has been recommended by
the Committee for Medicinal Products for Human Use of the European
Medicines Agency for the treatment of adult patients for whom
chemotherapy isn't clinically indicated.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
November 14, 2022 02:29 ET (07:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024